C3-Glomerulopathie - Herausforderungen in der Diagnose und Therapie

Zusammenfassung

Der Begriff C3-Glomerulopathie (C3G) beinhaltet die C3-Glomerulonephritis (C3 GN) und Dense Deposit Disease (DDD). Die C3G ist eine seltene Erkrankung der Niere, die geschätzte globale jährliche Inzidenz liegt bei 1–3 Fällen pro Million Menschen. Die C3G kann in jeder Altersgruppe auftreten, ist aber am häufigsten bei Kindern und jungen Erwachsenen [1]. Die klinische Präsentation variiert von einer asymptomatischen Hämaturie bis zu einer halbmondbildenden rapid-progressiven Glomerulonephritis (RPGN).

Publication History

Article published online:
07 November 2025

• Literatur

• 1 Caravaca-Fontán F, Lucientes L, Cavero T. et al. Update on C3 Glomerulopathy: A Complement-Mediated Disease. Nephron 2020; 144: 272-280
• 2 Barbour TD, Pickering MC, Terence Cook H. Dense deposit disease and C3 glomerulopathy. Semin Nephrol 2013; 33: 493-507
• 3 Bomback AS, Santoriello D, Avasare RS. et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 2018; 93: 977-985
• 4 Smith RJH, Appel GB, Blom AM. et al. C3 glomerulopathy – understanding a rare complement-driven renal disease. Nat Rev Nephrol 2019; 15: 129-143
• 5 Bomback AS, Daina E, Remuzzi G. et al. Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis. Kidney Int Rep 2025; 10: 87-98
• 6 Pickering MC, D’Agati VD, Nester CM. et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84: 1079-1089
• 7 Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol 2015; 11: 14-22
• 8 Nasr SH, Valeri AM, Appel GB. et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009; 4: 22-32
• 9 Sethi S, Gamez JD, Vrana JA. et al. Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75: 952-960
• 10 Hou J, Markowitz GS, Bomback AS. et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 2014; 85: 450-456
• 11 Vivarelli M, van de Kar N, Labbadia R. et al. A clinical approach to children with C3 glomerulopathy. Pediatr Nephrol 2022; 37: 521-535
• 12 Iatropoulos P, Noris M, Mele C. et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol 2016; 71: 131-142
• 13 Iatropoulos P, Daina E, Curreri M. et al. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. J Am Soc Nephrol 2018; 29: 283-294
• 14 Garam N, Prohászka Z, Szilágyi Á. et al. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. Orphanet J Rare Dis 2019; 14: 247
• 15 Garam N, Prohászka Z, Szilágyi Á. et al. Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis. Clin Kidney J 2020; 13: 225-234
• 16 Al-Ghaithi B, Chanchlani R, Riedl M. et al. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum. Pediatr Nephrol 2016; 31: 2079-2086
• 17 Rodriguez-Iturbe B, Musser JM. The current state of poststreptococcal glomerulonephritis. J Am Soc Nephrol 2008; 19: 1855-1864
• 18 Sethi S, Fervenza FC, Zhang Y. et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 2013; 83: 293-299
• 19 Kidney Disease. Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100 S1–S276
• 20 Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2012; 8: 634-642
• 21 Ravindran A, Fervenza FC, Smith RJH. et al. C3 Glomerulopathy: Ten Years’ Experience at Mayo Clinic. Mayo Clin Proc 2018; 93: 991-1008
• 22 Corvillo F, Okrój M, Nozal P. et al. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations. Front Immunol 2019; 10: 886
• 23 Prohászka Z, Nilsson B, Frazer-Abel A. et al. Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control. Immunobiology 2016; 221: 1247-1258
• 24 Servais A, Noël LH, Roumenina LT. et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82: 454-464
• 25 Zhang Y, Nester CM, Martin B. et al. Defining the complement biomarker profile of C3 glomerulopathy. Clin J Am Soc Nephrol 2014; 9: 1876-1882
• 26 Vivarelli M, Barratt J, Beck Jr. LH. et al. The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2024; 106: 369-391
• 27 Nicolas C, Vuiblet V, Baudouin V. et al. C3 nephritic factor associated with C3 glomerulopathy in children. Pediatr Nephrol 2014; 29: 85-94
• 28 Michels M, van de Kar N, van Kraaij SAW. et al. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Front Immunol 2021; 12: 715704
• 29 Goodship TH, Cook HT, Fakhouri F. et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2017; 91: 539-551
• 30 Ravindran A, Fervenza FC, Smith RJH. et al. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int 2018; 94: 178-186
• 31 Rabasco C, Cavero T, Román E. et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015; 88: 1153-1160
• 32 Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L. et al. Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. Clin J Am Soc Nephrol 2020; 15: 1287-1298
• 33 Noris M, Remuzzi G. C3G and Ig-MPGN—treatment standard. Nephrol Dial Transplant 2023; 39: 202-214
• 34 Khandelwal P, Bhardwaj S, Singh G. et al. Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. Pediatr Nephrol 2021; 36: 591-600
• 35 Bagheri N, Nemati E, Rahbar K. et al. Cyclosporine in the treatment of membranoproliferative glomerulonephritis. Arch Iran Med 2008; 11: 26-29
• 36 Avasare RS, Canetta PA, Bomback AS. et al. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series. Clin J Am Soc Nephrol 2018; 13: 406-413
• 37 Giaime P, Daniel L, Burtey S. Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy. Clin Nephrol 2015; 83: 57-60
• 38 Rousset-Rouvière C, Cailliez M, Garaix F. et al. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 2014; 29: 1107-1111
• 39 Rudnicki M. Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies. Biomed Res Int 2017; 2017: 2180508
• 40 Le Quintrec M, Lapeyraque AL, Lionet A. et al. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. Am J Kidney Dis 2018; 72: 84-92
• 41 Bomback AS, Smith RJ, Barile GR. et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748-756
• 42 Bomback AS, Kavanagh D, Vivarelli M. et al. Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial. Kidney Int Rep 2022; 7: 2150-2159
• 43 Nester C, Smith R, Kavanagh D. et al. WCN25–2041 efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-month results from the phase 3 APPEAR-C3G study. Kidney Int Rep 2025; 10: S136-S137
• 44 Nester CM, Bomback AS, Ariceta Iraola MG. et al. VALIANT: A Randomized, Multicenter, Double-Blind, Placebo (PBO)-Controlled, Phase 3 Trial of Pegcetacoplan for Patients with Native or Post-transplant Recurrent Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): SA-OR92. J Am Soc Nephrol 2024; 35
• 45 Caravaca-Fontán F, Lucientes L, Serra N. et al. C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies. Nephrol Dial Transplant 2022; 37: 2128-2137